Hope often comes with a disclaimer.
That was the unspoken sentiment last week when the U.S. Food and Drug Administration (FDA) approved the biologic drug Nucala (mepolizumab) for use in treating a subset of patients with chronic obstructive pulmonary disease (COPD). Heralded by its manufacturer, GSK, as a breakthrough for those suffering from eosinophilic inflammation—a rare but hard-to-treat form of COPD—the approval was widely reported as a win for innovation in a stagnant therapeutic landscape.
But beneath the surface of that announcement lies a murkier story. One not only of scientific merit, but of political maneuvering, financial entanglements, and the troubling permeability between regulatory agencies and the industries they oversee.
What Is Nucala and Why Does It Matter?
Nucala is a monoclonal antibody previously approved for severe eosinophilic asthma, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis. Its mechanism targets interleukin-5 (IL-5), a cytokine responsible for the survival of eosinophils—a type of white blood cell that, when elevated, contributes to chronic inflammation in both asthma and COPD.
According to WebMD, Nucala’s new indication allows it to be prescribed for adults with eosinophilic COPD who continue to have exacerbations despite maximum inhaled therapy. While this represents a small segment of COPD patients, it is a population with limited options and high morbidity.
On clinical merit, the approval appears well-supported. Phase III trials showed a reduction in moderate to severe flare-ups by approximately 20% in patients with elevated eosinophils. But even as the data speaks, the surrounding political silence speaks louder.
The FDA and the Pharmaceutical Carousel
The FDA’s drug approval process is often lauded for its scientific rigor—but that rigor is increasingly compromised by structural dependencies.
According to the New England Journal of Medicine, more than 45% of the FDA’s budget for drug evaluation now comes from industry user fees—direct payments from pharmaceutical companies intended to speed up review times under the Prescription Drug User Fee Act (PDUFA). In theory, this improves efficiency. In practice, it creates a revolving door.
The approval of Nucala was overseen by advisory committees that included several physicians with previous or ongoing financial relationships with GSK or its competitors. While disclosures were made, the ubiquity of such conflicts of interest dilutes the meaning of transparency itself.
Critics, including former FDA officials, argue that the agency’s dual role—both regulator and facilitator of drug development—has blurred the line between oversight and endorsement.
Lobbying, Access, and the Market for Breath
GSK, like many pharmaceutical giants, is no stranger to Washington. In 2023 alone, it spent over $7.8 million on federal lobbying efforts, much of it directed toward healthcare policy, drug pricing, and accelerated approval pathways.
A closer look at congressional records reveals that COPD—despite being a leading cause of death in the U.S.—has received limited legislative attention. This gap has created fertile ground for industry-driven narratives to dominate regulatory discourse.
The push for Nucala’s approval followed a familiar playbook: direct-to-consumer advertising, condition-specific awareness campaigns, and heavy investment in publication strategy. The result is not just approval—it’s market shaping.
The Ethics of Incrementalism
The medical community remains divided on whether Nucala’s benefits justify its costs. The drug is priced at approximately $32,000 annually per patient—a cost borne largely by public payers like Medicare.
Dr. Leena Jain, a pulmonary specialist writing in The BMJ, noted that while the reduction in exacerbations is statistically significant, it may not be clinically transformative. “We must ask,” she wrote, “whether the marginal benefit is worth the economic burden—and who ultimately profits from this exchange.”
This dilemma—incremental benefit at maximal cost—is not new. But it is becoming increasingly common in the biologics market, where marginal improvements are monetized as miracles.
Regulatory Capture or Necessary Expediency?
Is this regulatory capture—or simply the cost of doing science in a capitalist society?
Defenders of the approval argue that drug development is inherently expensive and that public-private collaboration is necessary to deliver innovation. They point to the long, costly path of biologic therapies, where each molecule represents a decade of research.
But critics note that most of that research is publicly funded. The Institute for New Economic Thinking estimates that over 75% of the foundational science behind FDA-approved drugs traces back to NIH-funded projects. The public, in other words, pays twice: once for discovery, and again at the pharmacy.
Conclusion: The Politics of Pulmonary Care
Nucala’s approval for COPD may help a small group of patients breathe easier. But it also reminds us that behind every headline of medical progress lies a bureaucracy of bias, influence, and uneven incentives.
In an era when trust in public institutions is faltering, the FDA must do more than approve drugs. It must explain—clearly, candidly, and independently—why it approves them.
Otherwise, each new approval, no matter how scientifically justified, risks becoming another example of medicine’s deepest paradox:
A cure for the body, born in a system that still struggles to breathe ethically.
